Controversies in the management of colorectal liver metastases: Role of PET and PET/CT

Digestive Surgery

Volumn 25, Issue 6, 2009, Pages 413-420

  Wiering, Bastiaan ^a   Vogel, Wouter V ^b   Ruers, Theo J M ^b   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Colorectal cancer; FDG PET; Liver metastases; PET CT

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; MEDICAL LITERATURE; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

BIOPSY, NEEDLE; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CRYOSURGERY; DIAGNOSTIC IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 60149110644     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000184732     Document Type: Conference Paper

References (56)

1. Gayowski TJ, Iwatsuki S, Madariaga JR, et al: Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994;116:703-710.
2. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703-707.
3. Langenhoff BS, Oyen WJ, Jager GJ, et al: Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453-4458.
4. Ruers TJ, Langenhoff BS, Neeleman N, et al: Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-395.
5. Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ: Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007;14:818-826.
6. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL: Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging 2004;29:663-668.
7. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA: Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-1034.
8. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H: Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 2006;16:80-87.
9. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA: Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 2006;141:1220-1226.
10. Riedl CC, Akhurst T, Larson S, et al: 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771-775.
11. Rohren EM, Paulson EK, Hagge R, et al: The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002;27:550-555.
12. Dromain C, de Baere T, Elias D, et al: Hepatic tumors treated with percutaneous radiofrequency ablation: CT and MR imaging follow-up. Radiology 2002;223:255-262.
13. Lim HK, Choi D, Lee WJ, et al: Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001;221:447-454.
14. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438-447.
15. Horst S, Kocak E, Young D, Mantil J, Martin EW Jr: Abdominal positron-emission tomography lesions with increased standardized uptake values correlate with intraoperative findings. Am J Surg 2006;191:39-44.
16. King J, Glenn D, Clark W, et al: Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg 2004;91:217-223.
17. Steinke K, Glenn D, King J, et al: Percutaneous imaging-guided radiofrequency ablation in patients with colorectal pulmonary metastases: 1-year follow-up. Ann Surg Oncol 2004;11:207-212.
18. Lowe VJ, Fletcher JW, Gobar L, et al: Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-1084.
19. Bohdiewicz PJ, Wong CY, Kondas D, Gaskill M, Dworkin HJ: High predictive value of F-18 FDG PET patterns of the spine for metastases or benign lesions with good agreement between readers. Clin Nucl Med 2003;28:966-970.
20. Ishimori T, Patel PV, Wahl RL: Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005;46:752-757.
21. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M: Routine (18)FFDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784-1788.
22. Pessaux P, Lermite E, Brehant O, Tuech JJ, Lorimier G, Arnaud JP: Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006;93:1-7.
23. Petrowsky H, Gonen M, Jarnagin W, et al: Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002;235:863-871.
24. Sobhani I, Tiret E, Lebtahi R, et al: Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008;98:875-880.
25. Chua SC, Groves AM, Kayani I, et al: The impact of 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007;34:1906-1914.
26. Blokhuis TJ, van der Schaaf MC, van den Tol MP, Comans EF, Manoliu RA, van der Sijp JR: Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol Suppl 2004;241:93-97.
27. Antoch G, Vogt FM, Veit P, et al: Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005;46:520-525.
28. Reimer P, Balzer T: Advantages and differences of Resovist towards gadolinium contrast in MRI with focus on metastatic liver lesions. Eur Radiol 2004;14(suppl 1):C4.
29. Fong Y, Saldinger PF, Akhurst T, et al: Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178: 282-287.
30. Flamen P, Hoekstra OS, Homans F, et al: Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-869.
31. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-511.
32. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA: Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-323.
33. Findlay M, Young H, Cunningham D, et al: Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-708.
34. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J: PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003;47:8-13.
35. Francis DL, Visvikis D, Costa DC, et al: Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET. Eur J Nucl Med Mol Imaging 2004;31:928.
36. Cohade C, Osman M, Leal J, Wahl RL: Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797-1803.
37. Ohlsson B, Nilsson J, Stenram U, Akerman M, Tranberg KG: Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours. Br J Surg 2002;89:757-762.
38. Vergara V, Garripoli A, Marucci MM, Bonino F, Capussotti L: Colon cancer seeding after percutaneous fine needle aspiration of liver metastasis. J Hepatol 1993;18:276-278.
39. Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH: PET/CT: panacea, redundancy, or something in between? J Nucl Med 2004;45(suppl 1):15S-24S.
40. Vogel WV, van Dalen JA, Wiering B, et al: Evaluation of image registration in PET/CT of the liver and recommendations for optimized imaging. J Nucl Med 2007;48:910-919.
41. van Dalen JA, Vogel W, Huisman HJ, Oyen WJ, Jager GJ, Karssemeijer N: Accuracy of rigid CT-FDG-PET image registration of the liver. Phys Med Biol 2004;49:5393-5405.
42. Kim JH, Czernin J, Allen-Auerbach MS, et al: Comparison between 18F-FDG PET, inline PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005;46:587-595.
43. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL: Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003;44:240-243.
44. Goerres GW, Ziegler SI, Burger C, Berthold T, von Schulthess GK, Buck A: Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology 2003;226:577-584.
45. Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C: Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003;44:732-738.
46. Nakamoto Y, Chin BB, Cohade C, Osman M, Tatsumi M, Wahl RL: PET/CT: artifacts caused by bowel motion. Nucl Med Commun 2004;25:221-225.
47. Sahani DV, Kalva SP, Fischman AJ, et al: Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005;185:239-246.
48. Lejeune C, Bismuth MJ, Conroy T, et al: Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005;46:2020-2028.
49. Park KC, Schwimmer J, Shepherd JE, et al: Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001;233:310-319.
50. Zubeldia JM, Bednarczyk EM, Baker JG, Nabi HA: The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases. Cancer Biother Radiopharm 2005;20:450-456.
51. Francis DL, Freeman A, Visvikis D, et al: In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-1606.
52. Laverman P, Boerman OC, Corstens FH, Oyen WJ: Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 2002;29:681-690.
53. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-994.
54. Hofmann M, Maecke H, Borner R, et al: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTA-TOC: preliminary data. Eur J Nucl Med 2001;28:1751-1757.
55. Jamar F, Barone R, Mathieu I, et al: 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-518.
56. Wester HJ, Brockmann J, Rosch F, et al: PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. Nucl Med Biol 1997;24: 275-286.